Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review

Kiran Patel, Vice President, Clinical Development, Solid Tumors, Johnson & Johnson Innovative Medicine Johnson & Johnson’s Janssen Japan unit will make inroads into the lung cancer market, with a recently filed EGFR-targeted combination therapy expected to be its first product...read more